{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:58:11Z","timestamp":1788692291505,"version":"build-2803163510"},"reference-count":201,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UID\/04567\/2025"],"award-info":[{"award-number":["UID\/04567\/2025"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119149","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:38:19Z","timestamp":1783697899000},"page":"119149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Drugging p53 mutants: Recent advances using small-molecule modulation strategies"],"prefix":"10.1016","volume":"318","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5746-4058","authenticated-orcid":false,"given":"Elizabeth A.","family":"Lopes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s G.","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.M.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119149_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/278261a0","article-title":"T antigen is bound to a host protein in SV40-transformed cells","volume":"278","author":"Lane","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119149_bib2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0042-6822(79)90250-2","article-title":"Identification of new polypeptide species (48\u201355K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells","volume":"93","author":"Melero","year":"1979","journal-title":"Virology"},{"key":"10.1016\/j.ejmech.2026.119149_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0092-8674(79)90293-9","article-title":"Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells","volume":"17","author":"Linzer","year":"1979","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119149_bib4","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1073\/pnas.76.5.2420","article-title":"Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse","volume":"76","author":"DeLeo","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.119149_bib5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1128\/jvi.31.2.472-483.1979","article-title":"Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum","volume":"31","author":"Kress","year":"1979","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119149_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0092-8674(79)90053-9","article-title":"Characterization of different tumor antigens present in cells transformed by simian virus 40","volume":"18","author":"Smith","year":"1979","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119149_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1073\/pnas.78.1.41","article-title":"Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein","volume":"78","author":"Crawford","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.119149_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1073\/pnas.80.1.56","article-title":"Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen","volume":"80","author":"Oren","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.119149_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.2649981","article-title":"Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas","volume":"244","author":"Baker","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119149_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/342705a0","article-title":"Mutations in the p53 gene occur in diverse human tumour types","volume":"342","author":"Nigro","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119149_bib11","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1073\/pnas.78.3.1695","article-title":"p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells","volume":"78","author":"Dippold","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.119149_bib12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/j.1460-2075.1982.tb01296.x","article-title":"Radioimmunoassay of the cellular protein p53 in mouse and human cell lines","volume":"1","author":"Benchimol","year":"1982","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.119149_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/316158a0","article-title":"Overproduction of p53 antigen makes established cells highly tumorigenic","volume":"316","author":"Eliyahu","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119149_bib14","first-page":"81","article-title":"Overexpression of normal human p53 in established fibroblasts leads to their tumorigenic conversion","volume":"4","author":"Tuck","year":"1989","journal-title":"Oncogene Res."},{"key":"10.1016\/j.ejmech.2026.119149_bib15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0092-8674(89)90045-7","article-title":"The p53 proto-oncogene can act as a suppressor of transformation","volume":"57","author":"Finlay","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119149_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/352345a0","article-title":"Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6","volume":"352","author":"Yonish-Rouach","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119149_bib17","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1073\/pnas.89.10.4495","article-title":"Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line","volume":"89","author":"Shaw","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.119149_bib18","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119149_bib19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/348747a0","article-title":"Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li\u2013Fraumeni syndrome","volume":"348","author":"Srivastava","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119149_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0092-8674(91)90560-L","article-title":"Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication","volume":"65","author":"Bargonetti","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119149_bib21","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1126\/science.2047879","article-title":"Identification of p53 as a sequence-specific DNA-Binding protein","volume":"252","author":"Kern","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119149_bib22","first-page":"1829","article-title":"A potential transcriptional activation element in the p53 protein","volume":"5","author":"O'Rourke","year":"1990","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119149_bib23","first-page":"2866","article-title":"A transcriptionally active DNA-binding site for human p53 protein complexes","volume":"12","author":"Funk","year":"1992","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119149_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/358083a0","article-title":"Wild-type p53 activates transcription in vitro","volume":"358","author":"Farmer","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119149_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1101\/gad.5.2.151","article-title":"Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein","volume":"5","author":"Martinez","year":"1991","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2026.119149_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119149_bib27","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-R","article-title":"The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation","volume":"69","author":"Momand","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119149_bib28","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1101\/gad.7.7a.1126","article-title":"The p53-mdm-2 autoregulatory feedback loop","volume":"7","author":"Wu","year":"1993","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2026.119149_bib29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119149_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/387299a0","article-title":"Regulation of p53 stability by Mdm2","volume":"387","author":"Kubbutat","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119149_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-5793(97)01480-4","article-title":"Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53","volume":"420","author":"Honda","year":"1997","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2026.119149_bib32","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1002\/j.1460-2075.1996.tb00919.x","article-title":"MDMX: a novel p53-binding protein with some functional properties of MDM2","volume":"15","author":"Shvarts","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.119149_bib33","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1126\/science.281.5383.1674","article-title":"Enhanced phosphorylation of p53 by ATM in response to DNA damage","volume":"281","author":"Banin","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119149_bib34","doi-asserted-by":"crossref","first-page":"31463","DOI":"10.1074\/jbc.274.44.31463","article-title":"Role of Human Cds1 (Chk2) kinase in DNA damage checkpoint and its regulation by p53","volume":"274","author":"Tominaga","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119149_bib35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1101\/gad.14.3.289","article-title":"The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites","volume":"14","author":"Shieh","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2026.119149_bib36","doi-asserted-by":"crossref","first-page":"8292","DOI":"10.1073\/pnas.95.14.8292","article-title":"Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2","volume":"95","author":"Kamijo","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.119149_bib37","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","article-title":"Noxa, a BH3-Only member of the Bcl-2 family and candidate mediator of p53-Induced apoptosis","volume":"288","author":"Oda","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119149_bib38","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","article-title":"PUMA, a novel proapoptotic gene, is induced by p53","volume":"7","author":"Nakano","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119149_bib39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119149_bib53","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.molcel.2006.05.015","article-title":"Structural basis of DNA recognition by p53 tetramers","volume":"22","author":"Kitayner","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119149_bib54","author":"Kitayner"},{"key":"10.1016\/j.ejmech.2026.119149_bib55","doi-asserted-by":"crossref","first-page":"9964","DOI":"10.1021\/bi1012996","article-title":"Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein","volume":"49","author":"Lee","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119149_bib56","author":"Lee"},{"key":"10.1016\/j.ejmech.2026.119149_bib57","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1126\/science.7878469","article-title":"Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms","volume":"267","author":"Jeffrey","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119149_bib58","author":"Jeffrey"},{"key":"10.1016\/j.ejmech.2026.119149_bib59","author":"Rustandi"},{"key":"10.1016\/j.ejmech.2026.119149_bib60","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/76797","article-title":"Structure of the negative regulatory domain of p53 bound to S100B(\u03b2\u03b2)","volume":"7","author":"Rust","year":"2000","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ejmech.2026.119149_bib40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1146\/annurev.biochem.77.060806.091238","article-title":"Structural biology of the tumor suppressor p53","volume":"77","author":"Joerger","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2026.119149_bib41","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.1073\/pnas.1903077116","article-title":"Interaction between p53 N terminus and core domain regulates specific and nonspecific DNA binding","volume":"116","author":"He","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.119149_bib42","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119149_bib43","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1073\/pnas.94.9.4675","article-title":"A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gas1","volume":"94","author":"Ruaro","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.119149_bib44","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/bip.22772","article-title":"Tetramer formation of tumor suppressor protein p53: structure, function, and applications","volume":"106","author":"Kamada","year":"2016","journal-title":"Biopolymers"},{"key":"10.1016\/j.ejmech.2026.119149_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108342","article-title":"Folding and structural polymorphism of p53 C-terminal domain: one peptide with many conformations","volume":"684","author":"Kumar","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2026.119149_bib46","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0022-2836(02)00848-3","article-title":"p53 contains large unstructured regions in its native State","volume":"322","author":"Bell","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119149_bib47","doi-asserted-by":"crossref","first-page":"E11302","DOI":"10.1073\/pnas.1814051115","article-title":"Long-range regulation of p53 DNA binding by its intrinsically disordered N-terminal transactivation domain","volume":"115","author":"Krois","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.119149_bib48","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119149_bib49","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.8023157","article-title":"Crystal structure of a p53 tumor Suppressor-DNA complex: understanding tumorigenic mutations","volume":"265","author":"Cho","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119149_bib50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.sbi.2020.11.005","article-title":"An integrated view of p53 dynamics, function, and reactivation","volume":"67","author":"Demir","year":"2021","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejmech.2026.119149_bib51","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.3390\/ijms20225605","article-title":"The rich world of p53 DNA binding targets: the role of DNA structure","volume":"20","author":"Br\u00e1zda","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119149_bib52","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.str.2009.11.011","article-title":"Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer","volume":"18","author":"Chen","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.119149_bib61","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119149_bib62","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41418-022-00989-y","article-title":"Mutant p53: it's not all one and the same","volume":"29","author":"Kennedy","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.119149_bib63","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-23-0402","article-title":"Loss-of-Function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival, and metastasis of a broad range of cancer cells","volume":"14","author":"Wang","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119149_bib64","article-title":"Molecule of the year","volume":"262","author":"Koshland","year":"1953","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119149_bib65","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/cdd.2017.171","article-title":"Deconstructing networks of p53-mediated tumor suppression in vivo","volume":"25","author":"Kaiser","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.119149_bib66","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.tcb.2024.06.003","article-title":"Deciphering the significance of p53 mutant proteins","volume":"35","author":"Butera","year":"2025","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119149_bib67","article-title":"Mutational landscape of TP53 across cancer types","author":"Abran","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2026.119149_bib68","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.119149_bib69","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.3390\/cancers14184499","article-title":"Targeting mutant p53 for cancer treatment: moving closer to clinical use?","volume":"14","author":"Duffy","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.119149_bib70","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.3390\/cancers13133344","article-title":"Structural and drug targeting insights on mutant p53","volume":"13","author":"Gomes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.119149_bib71","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fonc.2017.00323","article-title":"Synergistic rescue of nonsense mutant tumor suppressor p53 by combination treatment with aminoglycosides and Mdm2 inhibitors","volume":"7","author":"Zhang","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119149_bib72","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","article-title":"Mutant p53 gain of function in two mouse models of Li-Fraumeni Syndrome","volume":"119","author":"Olive","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119149_bib73","doi-asserted-by":"crossref","first-page":"7323","DOI":"10.2174\/0929867325666181116124308","article-title":"Small molecules targeting mutant p53: a promising approach for cancer treatment","volume":"26","author":"Lopes","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119149_bib74","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s12967-025-06566-4","article-title":"p53 in colorectal cancer: from a master player to a privileged therapy target","volume":"23","author":"Yan","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119149_bib75","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","article-title":"Mutant p53 suppresses innate immune signaling to promote tumorigenesis","volume":"39","author":"Ghosh","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119149_bib76","first-page":"1111","article-title":"Association of p53 mutations with metastatic prostate cancer","volume":"1","author":"Eastham","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119149_bib77","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/life12060897","article-title":"Multidrug resistance of cancer cells and the vital role of P-Glycoprotein","volume":"12","author":"Karthika","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.ejmech.2026.119149_bib78","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/cdd.2015.133","article-title":"DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53","volume":"23","author":"Alam","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.119149_bib79","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tips.2023.02.007","article-title":"Small-molecule correctors and stabilizers to target p53","volume":"44","author":"Fallatah","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.119149_bib80","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119149_bib81","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/cancers15020429","article-title":"Drugs targeting p53 mutations with FDA approval and in clinical trials","volume":"15","author":"Nishikawa","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.119149_bib82","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41571-023-00842-2","article-title":"Pharmacological reactivation of p53 in the era of precision anticancer medicine","volume":"21","author":"Tuval","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119149_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1529483","article-title":"Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53","volume":"16","author":"Taritsa","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119149_bib84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/ijmm.2024.5448","article-title":"TP53 mutations in cancer: molecular features and therapeutic opportunities","volume":"55","author":"Tornesello","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119149_bib85","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.18632\/oncotarget.6775","article-title":"Reactivation of wild-type and mutant p53 by tryptophanol-derived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule","volume":"7","author":"Soares","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.119149_bib86","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2174\/1568026618666180604080119","article-title":"An update on MDMX and dual MDM2\/X inhibitors","volume":"18","author":"Espadinha","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119149_bib87","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/cmdc.202000522","article-title":"Potency and selectivity optimization of tryptophanol-derived oxazoloisoindolinones: novel p53 activators in human colorectal cancer","volume":"16","author":"Barcherini","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119149_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114637","article-title":"Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors","volume":"241","author":"Espadinha","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119149_bib89","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1039\/D3MD00251A","article-title":"Hybrid molecules of protoflavones and spirooxindole derivatives with selective cytotoxicity against triple-negative breast cancer cells","volume":"14","author":"Girst","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119149_bib90","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/21541264.2025.2452711","article-title":"Harnessing p53 for targeted cancer therapy: new advances and future directions","volume":"16","author":"Andrysik","year":"2025","journal-title":"Transcription"},{"key":"10.1016\/j.ejmech.2026.119149_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41418-024-01259-9","article-title":"Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control?","volume":"32","author":"Janic","year":"2025","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.119149_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2019.129440","article-title":"SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations","volume":"1864","author":"Gomes","year":"2020","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.ejmech.2026.119149_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1148389","article-title":"The role of p53 in anti-tumor immunity and response to immunotherapy","volume":"10","author":"Carlsen","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2026.119149_bib94","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/pharmrev.123.001026","article-title":"MDM2 inhibitors for cancer therapy: the past, present, and future","volume":"76","author":"Wang","year":"2024","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2026.119149_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1529483","article-title":"Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53","volume":"16","author":"Taritsa","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119149_bib96","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/acschembio.9b00748","article-title":"Targeting cavity-creating p53 cancer mutations with small-molecule stabilizers: the Y220X paradigm","volume":"15","author":"Bauer","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119149_bib97","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1021\/acs.jmedchem.5c00670","article-title":"Rezatapopt (PC14586): a first-in-class small molecule p53 Y220C mutant protein stabilizer in clinical trials","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119149_bib98","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1038\/s41467-021-27142-6","article-title":"Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)","volume":"12","author":"Degtjarik","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119149_bib99","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41418-025-01549-w","article-title":"The roles of mutant p53 in reprogramming and inflammation in breast cancers","volume":"32","author":"Kummar","year":"2025","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.119149_bib100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ccell.2024.01.008","article-title":"Characterization of the generic mutant p53-rescue compounds in a broad range of assays","volume":"42","author":"Xiao","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119149_bib101","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41419-024-06739-x","article-title":"Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators","volume":"15","author":"Balourdas","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.119149_bib102","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/2159-8290.CD-24-1421","article-title":"Restoration of the tumor suppressor function of Y220C-Mutant p53 by rezatapopt, a small-molecule reactivator","volume":"15","author":"Puzio-Kuter","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119149_bib103","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3390\/biom10040635","article-title":"Recent synthetic approaches towards small molecule reactivators of p53","volume":"10","author":"Silva","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2026.119149_bib106","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2020.11.013","article-title":"Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119149_bib107","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn9155","article-title":"Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties","volume":"15","author":"Song","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119149_bib108","author":"Lu"},{"key":"10.1016\/j.ejmech.2026.119149_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110622","article-title":"Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations","volume":"39","author":"Tang","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119149_bib110","author":"Lu"},{"key":"10.1016\/j.ejmech.2026.119149_bib111","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acsmedchemlett.4c00379","article-title":"Discovery of Rezatapopt (PC14586), a First-in-Class, small-molecule reactivator of p53 Y220C Mutant in development","volume":"16","author":"Vu","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119149_bib112","author":"Abendroth"},{"key":"10.1016\/j.ejmech.2026.119149_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108982","article-title":"A selective p53 activator and anticancer agent to improve colorectal cancer therapy","volume":"35","author":"Ramos","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119149_bib114","article-title":"p53Y220C-BET-bifunctionals (tPRIMEs) drive p53Y220C-mutant cancer cells into apoptosis","author":"Kelley","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2026.119149_bib115","article-title":"Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs","author":"Sadagopan","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119149_bib116","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-LB428","article-title":"Abstract LB428: an orally bioavailable RIPTAC\u2122 therapeutic for p53 Y220C mutant tumors","volume":"85","author":"Lupey-Green","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119149_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1191","article-title":"Selective degradation of the p53-R175H oncogenic hotspot mutant by an RNA aptamer-based PROTAC","volume":"13","author":"Kong","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119149_bib118","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.scib.2024.05.017","article-title":"An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer","volume":"69","author":"Kong","year":"2024","journal-title":"Science Bulletin"},{"key":"10.1016\/j.ejmech.2026.119149_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2016.00021","article-title":"Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy","volume":"6","author":"Bykov","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119149_bib105","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41419-018-0463-7","article-title":"APR-246 reactivates mutant p53 by targeting cysteines 124 and 277","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.119149_bib131","author":"Degtjarik"},{"key":"10.1016\/j.ejmech.2026.119149_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2008.08.006","article-title":"Glutathione: overview of its protective roles, measurement, and biosynthesis","volume":"30","author":"Forman","year":"2009","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.ejmech.2026.119149_bib120","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jmb.2009.11.013","article-title":"Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function","volume":"395","author":"Lubin","year":"2010","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119149_bib121","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1038\/sj.onc.1208419","article-title":"PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis","volume":"24","author":"Bykov","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119149_bib122","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119149_bib123","first-page":"1343","article-title":"The mutant p53-Targeting compound APR-246 induces ROS-Modulating genes in breast cancer cells, Transl","volume":"11","author":"Synnott","year":"2018","journal-title":"Oncol"},{"key":"10.1016\/j.ejmech.2026.119149_bib124","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/s41375-022-01634-w","article-title":"APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations","volume":"36","author":"Hong","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.119149_bib125","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-10-3168","article-title":"PRIMA-1Met\/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53","volume":"17","author":"Zandi","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119149_bib126","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1158\/1535-7163.MCT-12-1166","article-title":"PRIMA-1Met\/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and noxa","volume":"12","author":"Saha","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119149_bib127","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in Vivo: a first-in-human Study with p53-Targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119149_bib128","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-Mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119149_bib129","series-title":"Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination with Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes","year":"2021"},{"key":"10.1016\/j.ejmech.2026.119149_bib130","author":"Therapeutics"},{"key":"10.1016\/j.ejmech.2026.119149_bib132","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2159-8290.CD-22-0381","article-title":"A small molecule reacts with the p53 somatic mutant Y220C to rescue wild-type thermal stability","volume":"13","author":"Guiley","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119149_bib135","author":"Guiley"},{"key":"10.1016\/j.ejmech.2026.119149_bib133","doi-asserted-by":"crossref","first-page":"222","DOI":"10.7555\/JBR.37.20230093","article-title":"Anticancer therapeutic strategies for targeting mutant p53-Y220C","volume":"38","author":"Chasov","year":"2024","journal-title":"J. Biomed. Res."},{"key":"10.1016\/j.ejmech.2026.119149_bib134","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41420-025-02781-6","article-title":"Cellular activity upregulation of the thermolabile p53 cancer mutant Y220C by small molecule indazole derivatives","volume":"11","author":"Khadiullina","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2026.119149_bib136","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1007\/s11030-024-11095-1","article-title":"Discovery of novel covalent stabilizers for p53 Y220C using structure-based drug discovery methods","volume":"29","author":"Wen","year":"2025","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2026.119149_bib137","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1021\/acsptsci.4c00414","article-title":"Covalent fragments acting as tyrosine mimics for mutant p53-Y220C rescue by Nucleophilic aromatic substitution","volume":"7","author":"Klett","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.119149_bib138","article-title":"Discovery of Electrophilic degraders that exploit SNAr chemistry","author":"Zhuang","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2026.119149_bib139","series-title":"p53-Y220C Core Domain Covalently Bound to 2,5,6-trifluoropyridine-3-carbonitrile Soaked at 40 Mm","author":"Stahlecker","year":"2024"},{"key":"10.1016\/j.ejmech.2026.119149_bib140","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1021\/acsptsci.5c00110","article-title":"Mechanistic insights of a p53-Targeting small molecule","volume":"8","author":"Ferreira","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.119149_bib141","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.2147\/DDDT.S513792","article-title":"SNAr reactive pyrazine derivatives as p53-Y220C cleft binders with diverse binding modes","volume":"19","author":"Klett","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2026.119149_bib142","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/cancers10060166","article-title":"Zinc metallochaperones as mutant p53 reactivators: a new paradigm in cancer therapeutics","volume":"10","author":"Kogan","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.119149_bib143","doi-asserted-by":"crossref","first-page":"41363","DOI":"10.18632\/oncotarget.9133","article-title":"COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo","volume":"7","author":"Salim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.119149_bib144","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ijrobp.2015.12.272","article-title":"A novel third generation thiosemicarbazone, COTI-2, is highly effective in killing head and neck squamous cell Carcinomas (HNSCC) bearing a variety of TP53 mutations","volume":"94","author":"Silver","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejmech.2026.119149_bib145","doi-asserted-by":"crossref","first-page":"13719","DOI":"10.1021\/acs.jmedchem.0c01277","article-title":"Cancer cell resistance against the clinically investigated thiosemicarbazone COTI-2 is based on Formation of intracellular copper complex glutathione adducts and ABCC1-Mediated efflux","volume":"63","author":"Bormio Nunes","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119149_bib146","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-19-0096","article-title":"COTI-2, A novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms","volume":"25","author":"Lindemann","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119149_bib148","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.33197","article-title":"Drugging \u201cundruggable\u201d genes for cancer treatment: are we making progress?","volume":"148","author":"Duffy","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119149_bib149","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1021\/acs.jmedchem.0c01360","article-title":"Benzothiazolyl and benzoxazolyl hydrazones function as zinc metallochaperones to reactivate mutant p53","volume":"64","author":"Gilleran","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119149_bib150","doi-asserted-by":"crossref","first-page":"17478","DOI":"10.1074\/jbc.M111.231639","article-title":"Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression","volume":"286","author":"Yan","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119149_bib152","author":"Yang"},{"key":"10.1016\/j.ejmech.2026.119149_bib154","author":"Hospital"},{"key":"10.1016\/j.ejmech.2026.119149_bib155","author":"Ruijin"},{"key":"10.1016\/j.ejmech.2026.119149_bib156","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-021-00337-1","article-title":"ATO stabilizes structural p53 mutants","volume":"21","author":"Gummlich","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119149_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110622","article-title":"Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations","volume":"39","author":"Tang","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119149_bib158","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.chembiol.2022.07.003","article-title":"Discovery of compounds that reactivate p53 mutants in vitro and in vivo","volume":"29","author":"Durairaj","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119149_bib159","article-title":"Activating p53Y220C with a mutant-specific small molecule","author":"Zhu","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2026.119149_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101201","article-title":"Rezatapopt: a promising small-molecule \u201crefolder\u201d specific for TP53Y220C mutant tumors","volume":"67","author":"Papavassiliou","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejmech.2026.119149_bib161","series-title":"PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data from PYNNACLE Phase 2 Trial Across Multiple Solid Tumors with a TP53 Y220C Mutation","year":"2025"},{"key":"10.1016\/j.ejmech.2026.119149_bib162","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1056\/NEJMoa2508820","article-title":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C\u2013Mutated tumors","volume":"394","author":"Dumbrava Ecaterina","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119149_bib163","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41419-026-08492-9","article-title":"Targeting the p53 cancer mutants Y220C, Y220N, and Y220S with the small-molecule stabilizer rezatapopt","volume":"17","author":"Mavridi","year":"2026","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.119149_bib164","article-title":"AI-powered discovery of a novel p53-Y220C reactivator","volume":"13","author":"Zhou","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119149_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104376","article-title":"Protac 2.0: expanding the frontiers of targeted protein degradation","volume":"30","author":"Cornu","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119149_bib166","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202501111","article-title":"Insights into vepdegestrant (ARV-471): the first-in-class estrogen receptor proteolysis-targeting chimera approaching food and drug administration approval for breast cancer","volume":"21","author":"Tang","year":"2026","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119149_bib168","doi-asserted-by":"crossref","first-page":"45138","DOI":"10.1021\/acsomega.4c06177","article-title":"Promising proteolysis-targeting chimera for mutant p53-R175H","volume":"9","author":"Zhuang","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.119149_bib169","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1186\/s12885-025-14361-z","article-title":"Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition","volume":"25","author":"Goerg","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2026.119149_bib170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12943-025-02463-y","article-title":"Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications","volume":"24","author":"Yan","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119149_bib171","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119149_bib172","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-Molecule PROTACS: new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119149_bib173","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ddr.22026","article-title":"Progress of small molecules for targeted protein degradation: PROTACs and other technologies","volume":"84","author":"Zhao","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2026.119149_bib174","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","article-title":"Discovery of MD-224 as a First-in-Class, highly potent, and efficacious proteolysis targeting chimera Murine double minute 2 degrader capable of achieving complete and durable tumor regression","volume":"62","author":"Li","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119149_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108167","article-title":"Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth","volume":"301","author":"Lv","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119149_bib176","doi-asserted-by":"crossref","first-page":"12945","DOI":"10.1021\/acs.jcim.5c02062","article-title":"Mechanistic insights into the allosteric regulation of P53 Y220C by small-molecule stabilizers","volume":"65","author":"Wen","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119149_bib177","article-title":"GenSci128, an investigational cancer therapy from gensci pharmaceuticals","year":"2026","journal-title":"Receives FDA Orphan Drug Designation for Pancreatic Cancer"},{"key":"10.1016\/j.ejmech.2026.119149_bib178","series-title":"A Phase I, Multicenter, Multinational, open-label, first-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GenSci128 Tablet in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation","year":"2025"},{"key":"10.1016\/j.ejmech.2026.119149_bib179","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41587-020-00778-3","article-title":"Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries","volume":"39","author":"Kuljanin","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.119149_bib180","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.chembiol.2023.06.021","article-title":"Proteome-wide structural analysis identifies warhead- and coverage-specific biases in cysteine-focused chemoproteomics","volume":"30","author":"White","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119149_bib181","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.chembiol.2023.04.004","article-title":"CysDB: a human cysteine database based on experimental quantitative chemoproteomics","volume":"30","author":"Boatner","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119149_bib182","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202300712","article-title":"TAC-tics for leveraging proximity biology in drug discovery","volume":"25","author":"Nalawansha","year":"2024","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2026.119149_bib187","author":"Therapeutics"},{"key":"10.1016\/j.ejmech.2026.119149_bib188","article-title":"PiSARRO-R: p53 suppressor activation in platinum-resistant high grade serous ovarian cancer, a phase II study of systemic pegylated liposomal","author":"Therapeutics","year":"2017","journal-title":"Doxorubicin Chemotherapy With APR-246"},{"key":"10.1016\/j.ejmech.2026.119149_bib189","author":"Therapeutics"},{"key":"10.1016\/j.ejmech.2026.119149_bib190","article-title":"Phase II trial of APR-246 in combination with azacitidine as maintenance therapy for TP53 mutated AML or MDS following allogeneic","year":"2019","journal-title":"Stem Cell Transplant"},{"key":"10.1016\/j.ejmech.2026.119149_bib191","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-Mutant acute Myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119149_bib192","author":"Therapeutics"},{"key":"10.1016\/j.ejmech.2026.119149_bib193","series-title":"Phase I Study of APR-246 in Combination with Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies","year":"2019"},{"key":"10.1016\/j.ejmech.2026.119149_bib194","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejmech.2026.119149_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100573","article-title":"Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors","volume":"7","author":"Park","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejmech.2026.119149_bib197","author":"Therapeutics"},{"key":"10.1016\/j.ejmech.2026.119149_bib198","series-title":"Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms","article-title":"A phase 1b\/2 Study to evaluate the safety and efficacy of APR-246","year":"2017"},{"key":"10.1016\/j.ejmech.2026.119149_bib199","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: a Phase II Study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119149_bib201","series-title":"A Phase 1b\/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination with Azacitidine for the Treatment of Mutation TP53 (TP53) Mutant Myeloid Neoplasms","year":"2018"},{"key":"10.1016\/j.ejmech.2026.119149_bib202","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-Mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119149_bib203","author":"Anderson Cancer Center"},{"key":"10.1016\/j.ejmech.2026.119149_bib204","series-title":"A Phase 1\/2 open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","year":"2020"},{"key":"10.1016\/j.ejmech.2026.119149_bib207","author":"Anderson Cancer Center"},{"key":"10.1016\/j.ejmech.2026.119149_bib209","author":"Ruijin"},{"key":"10.1016\/j.ejmech.2026.119149_bib211","author":"Yang"},{"key":"10.1016\/j.ejmech.2026.119149_bib212","series-title":"Pharmacokinetics and Efficacy of GenSci128 Tablet in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation","article-title":"A phase I, multicenter, multinational, open-label, first-in-human Study to evaluate the safety, tolerability","year":"2025"},{"key":"10.1016\/j.ejmech.2026.119149_bib183","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202101176","article-title":"Patient-Derived organoids can guide personalized-therapies for patients with advanced breast cancer","volume":"8","author":"Chen","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2026.119149_bib184","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3390\/pharmaceutics15092274","article-title":"Translational pharmacokinetic\/pharmacodynamic modeling and simulation of Oxaliplatin and Irinotecan in colorectal cancer","volume":"15","author":"Zhu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119149_bib185","first-page":"25986","article-title":"Mapping full conformational transition dynamics of intrinsically disordered proteins using a single-molecule nanocircuit","volume":"18","author":"Yin","year":"2024","journal-title":"ACS Nano"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:18:18Z","timestamp":1788049098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":201,"alternative-id":["S0223523426005945"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119149","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugging p53 mutants: Recent advances using small-molecule modulation strategies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119149"}}